Matches in SemOpenAlex for { <https://semopenalex.org/work/W2473712574> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W2473712574 endingPage "62" @default.
- W2473712574 startingPage "457" @default.
- W2473712574 abstract "Thirty-nine previously untreated small cell lung cancer patients received cyclophosphamide (CTX) + adriamycin (ADM) + vincristine (VCR) (CAV). The doses initially used were CTX 1,000 mg/body day 1, ADM 50 mg/body day, VCR 1 mg/body day, 8, 15 or 2 mg/body day(group A). Later, CTX 1,000 mg/m2 day, ADM 60 mg/m2 day, VCR 1.4 mg/m2 day were used. All patients had PS 0-3, 24 had limited disease (LD) and 15, extensive disease (ED). The overall response rate and the complete response (CR) rates were 63% (15/24) and 21% (5/24) for LD, and 21% (3/14) and 0% (0/14) for ED, respectively. The median response durations were 22 weeks for LD and 33 weeks for ED. The median CR duration in LD patients was 23 weeks. Twelve LD and 1 ED patient received thoracic radiotherapy (RT) optionally after 2-4 courses of CAV therapy. Eventually, 8 patients achieved CR. The median survival for LD, ED and all cases were 43 weeks, 37 weeks and 41 weeks, respectively. The 1, 2 and 3-year survival rates were 42, 25 and 21% for LD, and 40, 7 and 0% for ED. Three patients were long-term disease-free survivors (greater than 3 years), and these had LD and received RT. There were 3 chemotherapy-related deaths (2 patients with leukopenia + infection, 1 patient with drug-induced pneumonitis). The survival results of CAV therapy in our hospital were comparable with the recent results of chemotherapies available against small cell lung cancer." @default.
- W2473712574 created "2016-07-22" @default.
- W2473712574 creator A5003703815 @default.
- W2473712574 creator A5005972478 @default.
- W2473712574 creator A5009766343 @default.
- W2473712574 creator A5011848451 @default.
- W2473712574 creator A5027022906 @default.
- W2473712574 creator A5059046154 @default.
- W2473712574 creator A5068719086 @default.
- W2473712574 creator A5071120983 @default.
- W2473712574 creator A5090226154 @default.
- W2473712574 date "1988-03-01" @default.
- W2473712574 modified "2023-09-23" @default.
- W2473712574 title "[Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer]." @default.
- W2473712574 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2831819" @default.
- W2473712574 hasPublicationYear "1988" @default.
- W2473712574 type Work @default.
- W2473712574 sameAs 2473712574 @default.
- W2473712574 citedByCount "1" @default.
- W2473712574 countsByYear W24737125742015 @default.
- W2473712574 crossrefType "journal-article" @default.
- W2473712574 hasAuthorship W2473712574A5003703815 @default.
- W2473712574 hasAuthorship W2473712574A5005972478 @default.
- W2473712574 hasAuthorship W2473712574A5009766343 @default.
- W2473712574 hasAuthorship W2473712574A5011848451 @default.
- W2473712574 hasAuthorship W2473712574A5027022906 @default.
- W2473712574 hasAuthorship W2473712574A5059046154 @default.
- W2473712574 hasAuthorship W2473712574A5068719086 @default.
- W2473712574 hasAuthorship W2473712574A5071120983 @default.
- W2473712574 hasAuthorship W2473712574A5090226154 @default.
- W2473712574 hasConcept C126322002 @default.
- W2473712574 hasConcept C141071460 @default.
- W2473712574 hasConcept C2776256026 @default.
- W2473712574 hasConcept C2776694085 @default.
- W2473712574 hasConcept C2776755627 @default.
- W2473712574 hasConcept C2777714996 @default.
- W2473712574 hasConcept C2779429289 @default.
- W2473712574 hasConcept C2779524853 @default.
- W2473712574 hasConcept C2780873365 @default.
- W2473712574 hasConcept C509974204 @default.
- W2473712574 hasConcept C71924100 @default.
- W2473712574 hasConcept C90924648 @default.
- W2473712574 hasConceptScore W2473712574C126322002 @default.
- W2473712574 hasConceptScore W2473712574C141071460 @default.
- W2473712574 hasConceptScore W2473712574C2776256026 @default.
- W2473712574 hasConceptScore W2473712574C2776694085 @default.
- W2473712574 hasConceptScore W2473712574C2776755627 @default.
- W2473712574 hasConceptScore W2473712574C2777714996 @default.
- W2473712574 hasConceptScore W2473712574C2779429289 @default.
- W2473712574 hasConceptScore W2473712574C2779524853 @default.
- W2473712574 hasConceptScore W2473712574C2780873365 @default.
- W2473712574 hasConceptScore W2473712574C509974204 @default.
- W2473712574 hasConceptScore W2473712574C71924100 @default.
- W2473712574 hasConceptScore W2473712574C90924648 @default.
- W2473712574 hasIssue "3" @default.
- W2473712574 hasLocation W24737125741 @default.
- W2473712574 hasOpenAccess W2473712574 @default.
- W2473712574 hasPrimaryLocation W24737125741 @default.
- W2473712574 hasRelatedWork W1970090775 @default.
- W2473712574 hasRelatedWork W2010590441 @default.
- W2473712574 hasRelatedWork W2045692796 @default.
- W2473712574 hasRelatedWork W2073519266 @default.
- W2473712574 hasRelatedWork W2157863266 @default.
- W2473712574 hasRelatedWork W2192451422 @default.
- W2473712574 hasRelatedWork W2414464287 @default.
- W2473712574 hasRelatedWork W2418393430 @default.
- W2473712574 hasRelatedWork W2473712574 @default.
- W2473712574 hasRelatedWork W2999872887 @default.
- W2473712574 hasVolume "15" @default.
- W2473712574 isParatext "false" @default.
- W2473712574 isRetracted "false" @default.
- W2473712574 magId "2473712574" @default.
- W2473712574 workType "article" @default.